Allogene Therapeutics Inc. (ALLO) shares are trading at lower $29.06 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $51.38.
To add more color to this target, the company’s high over the last year is $55.00 and the low is $17.43. Over the last 52 weeks, ALLO is down -7.45% while the S&P 500 is up 17.22%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, ALLO reported a profit of $1.84 million. Allogene Therapeutics Inc. also saw revenues increase to $68.04 million. In addition, ALLO has free cash flow of -$153.67 million as of 09-2020. The company’s EBITDA came in at -$64.81 million which compares well with its peers.
FREE CONFIDENTIAL REPORT
3 Stocks Set To Soar By January 1st, 2021
You have Successfully Subscribed!
ALLO Return on Equity (ROE) is -27.60%, and its Return on Assets is -25.00%. All told, it is clear that, ALLO needs to be on your watchlist.
Find out when ALLO reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ALLO has a short ratio of 15.20 and outstanding shares of 127.14M.
ALLO has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.49 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -2.13. Allogene Therapeutics Inc. ALLO also noted assets of $1.22 billion at the end of the last quarter. Investors should also keep an eye on sector updates as ALLO has historically followed its peers on positive news.
All told, Allogene Therapeutics Inc. ALLO has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ALLO represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Allogene Therapeutics Inc. ALLO is now commanding a market cap of 3.91B and a float of 70.34M. ALLO is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ALLO stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ALLO, either long or short, and we have not been compensated for this article.